Category Highly Important

Lighthouse Pharmaceuticals raises $12M plus $49.2M NIH grant to retest the gingipain hypothesis in Alzheimer's.

Profluent licenses AI-designed kilobase-scale recombinases to Lilly, validating protein design platforms in pharma.

EnteroBiotix and mbiomics close back-to-back rounds, signaling microbiome therapeutics still have backers.

Asgard Therapeutics reveals preclinical data for AT-108, a first-in-class in vivo cell reprogramming cancer immunotherapy.

Insilico Medicine nominates ISM0387, an AI-designed PRMT5 inhibitor, as its 30th preclinical candidate and first from its UAE team.

Lilly acquires Ajax Therapeutics for up to $2.3B before Phase 1 readout, betting on a Type II JAK2 inhibitor.

Four companies are mining the dark proteome for cancer targets. The same-30-targets problem may finally be cracking.

CREATE Medicines dosed first patient with MT-304, a first-in-class multi-immune in vivo CAR for HER2 tumors.